British biotech GW Pharmaceuticals (GWPH) reported positive safety and efficacy data from physicians treating epileptics with its drug Epidiolex, driving shares to an all-time high. GW plans to launch a more rigorous clinical trial of Epidiolex later this year. Leerink analyst Joseph Schwartz reiterated an outperform rating and raised his price target to 110 from 90. Shares rose 16.3% to 89.82 but fell 3.7% to 86.51 after hours.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- GW Pharmaceuticals